The compositions of low molecular weight therapeutics
1. A composition comprising a therapeutic agent and a low molecular weight alkyl (N, N disubstituted amino) atsetat.2. A composition according to claim 1, characterized in that the small molecule therapeutic agent is selected from the group consisting of a taxane and a compound belonging according biopharmaceutical classification system (BCS) to at least one of the classes 2, 3, or 4.3. A composition according to claim 2, wherein the taxane is a member of the group consisting of paclitaxel, docetaxel and their tesetaksela smesey.4. A composition according to claim 2, characterized in that said compound is a Class 2 BKS.5. A composition according to claim 4, characterized in that said compound is selected from the group consisting of lansoprazole, haloperidol, sulfasalazine and glibenklamida.6. A composition according to claim 2, characterized in that said compound is a Class 3 BKS.7. A composition according to claim 6, characterized in that said compound is selected from the group consisting of atenolol, glucosamine or salts thereof and tsimetidina.8. A composition according to claim 2, characterized in that said compound is a Class 4 BKS.9. A composition according to claim 8, wherein the compound is selected from the group consisting of furosemide, and chlorothiazide gidrohlortiazida.10. A composition according to claim 1, further comprising a physiologically acceptable nositel.11. A composition according to claim 1, characterized in that the alkyl (N, N disubstituted amino) acetate is dodecyl 2 (N, N dimethylamino) propionat.12. A composition according to claim 1, characterized in that the alkyl (N, N disubstituted amino) acetate hydrochloride is dodecyl 2 (N, N dimethylamino) propionata.13. A composition according to claim 1, characterized in that the low molecular weight therapeutic agents